argenx SE (ARGX)
1055.37
+26.86
(+2.61%)
USD |
NASDAQ |
Sep 02, 16:00
1055.52
+0.16
(+0.01%)
After-Hours: 20:00
argenx Research and Development Expense (Annual) : 1.356B for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 1.356B |
| December 31, 2024 | 975.49M |
| December 31, 2023 | 755.11M |
| December 31, 2022 | 561.54M |
| December 31, 2021 | 575.87M |
| December 31, 2020 | 370.49M |
| December 31, 2019 | 219.40M |
| December 31, 2018 | 98.06M |
| Date | Value |
|---|---|
| December 31, 2017 | 57.86M |
| December 31, 2016 | 34.54M |
| December 31, 2015 | 22.67M |
| December 31, 2014 | 16.59M |
| December 31, 2013 | 12.26M |
| December 31, 2012 | 13.96M |
| December 31, 2011 | 6.400M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Autolus Therapeutics Plc | 128.59M |
| Akari Therapeutics Plc | 2.822M |
| Forte Biosciences, Inc. | 58.25M |
| Evaxion AS | 9.691M |
| DBV Technologies SA | 107.12M |